CN108348612A - 包含氨基硫羟酸酯化合物或其药学上可接受的盐、与能够增加受试者的癌细胞中h2o2水平的化合物的组合 - Google Patents

包含氨基硫羟酸酯化合物或其药学上可接受的盐、与能够增加受试者的癌细胞中h2o2水平的化合物的组合 Download PDF

Info

Publication number
CN108348612A
CN108348612A CN201680066560.4A CN201680066560A CN108348612A CN 108348612 A CN108348612 A CN 108348612A CN 201680066560 A CN201680066560 A CN 201680066560A CN 108348612 A CN108348612 A CN 108348612A
Authority
CN
China
Prior art keywords
subject
level
levels
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680066560.4A
Other languages
English (en)
Chinese (zh)
Inventor
I·塞兰
G·夸什
M·派瑞兹-阿里尔
G·马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADVANCED BIODESIGN
Original Assignee
ADVANCED BIODESIGN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADVANCED BIODESIGN filed Critical ADVANCED BIODESIGN
Publication of CN108348612A publication Critical patent/CN108348612A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680066560.4A 2015-10-15 2016-10-14 包含氨基硫羟酸酯化合物或其药学上可接受的盐、与能够增加受试者的癌细胞中h2o2水平的化合物的组合 Pending CN108348612A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306650 2015-10-15
EP15306650.1 2015-10-15
PCT/EP2016/074682 WO2017064241A1 (en) 2015-10-15 2016-10-14 Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject

Publications (1)

Publication Number Publication Date
CN108348612A true CN108348612A (zh) 2018-07-31

Family

ID=54360386

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680066560.4A Pending CN108348612A (zh) 2015-10-15 2016-10-14 包含氨基硫羟酸酯化合物或其药学上可接受的盐、与能够增加受试者的癌细胞中h2o2水平的化合物的组合

Country Status (21)

Country Link
US (1) US10406125B2 (enExample)
EP (1) EP3362094B1 (enExample)
JP (1) JP7062592B2 (enExample)
CN (1) CN108348612A (enExample)
AR (1) AR106351A1 (enExample)
CA (1) CA3001201C (enExample)
CY (1) CY1123916T1 (enExample)
DK (1) DK3362094T3 (enExample)
ES (1) ES2870508T3 (enExample)
HR (1) HRP20210358T1 (enExample)
HU (1) HUE054247T2 (enExample)
IL (1) IL258658B (enExample)
LT (1) LT3362094T (enExample)
MX (1) MX377725B (enExample)
PL (1) PL3362094T3 (enExample)
PT (1) PT3362094T (enExample)
RS (1) RS61572B1 (enExample)
SI (1) SI3362094T1 (enExample)
SM (1) SMT202100270T1 (enExample)
WO (1) WO2017064241A1 (enExample)
ZA (1) ZA201802400B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3833657T (pt) * 2019-07-31 2022-09-28 Advanced Biodesign Compostos de aminotiolester e seus usos
EP4035666A1 (en) * 2021-01-29 2022-08-03 Advanced Biodesign Aminothiolester compound or derivative thereof for use as an immunomodulatory agent
FR3119314B1 (fr) * 2021-01-29 2025-01-10 Advanced Biodesign Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable
WO2025229179A1 (en) * 2024-05-03 2025-11-06 Advanced Biodesign Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032476A1 (en) * 2000-05-31 2007-02-08 Cnrs - Centre National De La Recherche Scientifique Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032476A1 (en) * 2000-05-31 2007-02-08 Cnrs - Centre National De La Recherche Scientifique Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HELENE PELICANO等: "ROS stress in cancer cells and therapeutic implications", 《DRUG RESISTANCE UPDATES》 *

Also Published As

Publication number Publication date
HK1251477A1 (en) 2019-02-01
AR106351A1 (es) 2018-01-03
WO2017064241A1 (en) 2017-04-20
BR112018007480A2 (pt) 2018-10-23
CY1123916T1 (el) 2022-05-27
IL258658A (en) 2018-06-28
ZA201802400B (en) 2020-01-29
US20180303773A1 (en) 2018-10-25
US10406125B2 (en) 2019-09-10
SMT202100270T1 (it) 2021-07-12
JP7062592B2 (ja) 2022-05-06
CA3001201C (en) 2023-07-11
HUE054247T2 (hu) 2021-08-30
SI3362094T1 (sl) 2021-04-30
EP3362094B1 (en) 2021-02-17
JP2018531995A (ja) 2018-11-01
MX2018004381A (es) 2018-05-11
ES2870508T3 (es) 2021-10-27
MX377725B (es) 2025-03-11
HRP20210358T1 (hr) 2021-04-16
DK3362094T3 (da) 2021-03-01
CA3001201A1 (en) 2017-04-20
PT3362094T (pt) 2021-04-15
LT3362094T (lt) 2021-05-10
PL3362094T3 (pl) 2021-10-11
IL258658B (en) 2021-04-29
EP3362094A1 (en) 2018-08-22
RS61572B1 (sr) 2021-04-29

Similar Documents

Publication Publication Date Title
Sun et al. Activation of the p62‐Keap1‐NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells
JP7474269B2 (ja) がんを治療するための組成物及び方法
Buondonno et al. Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma
US20230149378A1 (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use for the treatment of cancer
AU2014101470A4 (en) Method of using neferine for inducing cell death in apoptosis resistant cells through activation of ryanodine receptor and for treating apoptosis resistant cancer
CN108348612A (zh) 包含氨基硫羟酸酯化合物或其药学上可接受的盐、与能够增加受试者的癌细胞中h2o2水平的化合物的组合
El Gaafary et al. Arglabin, an EGFR receptor tyrosine kinase inhibitor, suppresses proliferation and induces apoptosis in prostate cancer cells
Archer et al. Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma
WO2018067769A1 (en) Compounds, compositions, and methods for inhibiting bacterial growth
US11583509B2 (en) Compound for treating cancer and diabetes
US20250241878A1 (en) Tyrosine and resveratrol derivatives as novel modulators of cellular serine adp-ribosylation
US20240016784A1 (en) Y box binding protein 1 inhibitors
HK1251477B (en) Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject
BR112018007480B1 (pt) Composição farmacêutica, uso de uma combinação e método para a seleção de um indivíduo
BR112018007310B1 (pt) Método in vitro para selecionar um indivíduo que sofre de um câncer
HK1251476B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
Luttman Exploiting Metabolic Vulnerabilities In Solid Tumors Treated With ABL Kinase Allosteric Inhibitors
Ha Bioinformatics-Assisted Drug Discovery for Cancer Treatment: Investigating Molecular Mechanisms and Therapeutic Efficacy of Repurposed Compounds
Csonka Selenocompounds as novel anticancer agents against resistant breast cancer and antibacterial agents in Chlamydia trachomatis D
Kaweesa Insights into Cytostatic and Cytotoxic Properties of the Natural Product Mensacarcin
Chawapun et al. Targeting the Phosphoinositide 3-Kinase Signaling Pathway and Epidermal Growth Factor Receptor: The Potential of Dimethylcardamonin-Derived Amino Acids in Triple-Negative Breast Cancer Therapy
Barbi de Moura et al. Mitochondrial Respiration-An Important Therapeutic Target in

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180731

RJ01 Rejection of invention patent application after publication